DOI QR코드

DOI QR Code

Massa Medicata Fermentata improves fatty liver in high fat diet-fed nonalcoholic fatty liver disease's mouse model

고지방식이 유도 비알콜성지방간 마우스 모델에서 육신국(六神麯)의 지방간(脂肪肝) 개선효과

  • Received : 2014.02.12
  • Accepted : 2014.03.19
  • Published : 2014.03.30

Abstract

Objectives : This study was undertaken to verify the effects of Massa Medicata Fermentata (MMF) on nonalcoholic fatty liver disease (NAFLD) using high fat diet-fed male mice. Methods : Fifty four male C57BL/6N mice (age matched) were used for all experiments. Nine standard chow diet-fed mice were used as normal group and forty five high fat diet-fed obese mice were randomly divided into 5 groups: control, atorvastatin-10mg/kg, MMF(1)-62.5mg/kg, MMF(2)-125mg/kg and MMF(3)-250mg/kg. After all groups were treated with several kinds of diets for 8 weeks, we measured body weight gain, adipose tissue weights, plasma lipid and glucose metabolism, visceral organ weights, histological analysis for liver on the mice. Results : MMF-treated mice had lower body weight gain compared with controls. Among MMF-treated mice, the effect was magnified in MMF(2). MMF(3)-treated mice had lower blood plasma total cholesterol (TC) and glucose level compared with controls. MMF decreased hepatic lipid accumulation, liver fibrosis and liver inflammation of mice compared with controls. The effects was maximized in MMF(2) and atorvastatin. Blood plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), ${\gamma}$-glutamyltransferase (${\gamma}$-GT) concentrations tends to be decreased by MMF compared with controls. Blood plasma AST, ALT, ${\gamma}$-GT concentrations and organ weights were not changed by MMF, indicating that all three kinds of MMF do not show any hepatotoxicity. Conclusions : These results suggest that MMF improves NAFLD by reducing body weight gain, hepatic lipid accumulation, liver fibrosis, liver inflammation.

Keywords

Massa Medicata Fermentata;NAFLD;liver fibrosis;total cholesterol

References

  1. Moon JS, Kang BG, Ryu EK, Choi SM. A study of syndrome index differentiation in obesity. J Korean Med Obes Res. 2007 ; 7(1) : 55-69.
  2. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004 ; 53 : 413-9. https://doi.org/10.1136/gut.2003.027581
  3. Park KS, Jang BK, Kwon KM, Chung WJ, Cho KB, Hwang JS, Ahn SH, Mun KC, Kim YH. Antioxidant status in nonalcoholic steatohepatitis. Korea J Hepatol. 2005 ; 11(2) : 135-43.
  4. Day CP, James OF. Steatohepatitis: a tale of two "hits"?. Gastroenterol. 1998 ; 114 : 842-5. https://doi.org/10.1016/S0016-5085(98)70599-2
  5. Kim MH, Jeoung SH, Lee SW, Kim HK, Park CS, Jeon BH, Oh HM, Rho MC. Effect of Vigna angularis on toll-like receptor activation and pro-inflammatory cytokine production. Korean J Oriental Physiol Pathol. 2012 ; 26(4) : 511-8.
  6. Cho KH, Park JH, Byun BH, Lee ES, Choi HY, Seo BI, Byun SH. Effect of Phaseoli Angularis Semen on biochemical and histological changes of rats fed high fat diet. J Korean Oriental Med. 2002 ; 23(4) : 1-8.
  7. Pak JU, Moon SJ, Moon G, Won JH. Effects of Seman Armenicae and Radix Trichosanthis on the iNOS expression and superoxide formation in the RAW264.7 cells. J Kor Oriental Oncol. 1999 ; 5(1) : 137-50.
  8. Jung WS, Seo SW, Cho JJ, Son JW, Park MC, Choi CM, Yeom RS, Hwang SW, Kim YW, Song DS, Chae YS, Choi WS, NO JE, Yun HR, Kim YM, Park SJ, Shin MK, Song HJ. Extrat of Xanthii Fructus down-regulate TLR-4 mediated murine peritoneal macrophage inflammatory response by limiting NO synthase and IkB-${\alpha}$ degradation. Kor J Herbology. 2006 ; 21(3) : 103-9.
  9. Baek GH, Cho SJ, Cho HJ, Hong GH, Kim HW, Cho SI. Effects of Anemarrhenae Rhizoma on anti-oxidative activities. Kor J Herbology. 2007 ; 22(3) : 101-7.
  10. Kam BS, Kim IR, Kim HC, Kook YB Park YK, Seo BI, Seo YB, Song HJ, Shin MK, Lee YJ, Lee YC, Lim KH, Cho SI, Jung JK, Ju YS, Choi HY. Herbal medicine. 1st ed. Seoul : Yougnglimsa. 2004 : 415-6.
  11. Ministry of Food and Drug Safety. Studies on the expansion of the negative list for food ingredients. 2009 : 239-42.
  12. Yoon MY, Cho YK. Comorbid diseases in nonalcoholic fatty liver disease. Korean J med. 2010 ; 79(5) : 490-4.
  13. National Institute of Food and Drug Safety Evaluation. Influence of dietary intake on non-alcoholic fatty liver disease in Korean. 2012 : 1.
  14. Gao XM, Zhong GS. Application of differential commonly used in clinical medicine(Traditional Chinese Medicine). 1st ed. Beijing : People's Medical Publishing House. 2003 : 389-91.
  15. Yun HR. GGH(3) reduces body weight gain and blood lipid metabolism in high fat diet-fed male mice C57BL/6N. DongEui Graduate School of Korean Medicine, a doctoral dissertation in Korean medicine. 2012 : 1-41.
  16. Lee SH, Lim SW, Lee YM, Seo JW, Kim DK. Inhibitory effects of Triticum aestivum L. extracts on liver lipid accumulation in high fat-fed nice. Kor J Pharmacogn. 2011 ; 42(4) : 309-16.
  17. Yun SH, Kim HJ. Treasured Mirror of Eastern Medicine. first edition. Gyeongsangnam-do : Donguibogam press. 2005 : 1735, 2008.
  18. Park SH. Nonalcoholic fatty liver disease: treatment. Korean J Med. 2010 ; 79(5) : 481-9.
  19. Ministry of Food and Drug Safety Oncology and Antibiotics Division. Is it ok with your liver? - Directions for the use of hepatitis medicine - Retrieved Nov. 30, 2011, from http://www.mfds.go.kr
  20. Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments. Nutrition. 2012 ; 28 : 722-6. https://doi.org/10.1016/j.nut.2011.11.017
  21. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol. 1999 ; 116 : 1413-9. https://doi.org/10.1016/S0016-5085(99)70506-8
  22. Park SH. Pharmacotherapy of nonalcoholic steatohepatitis. Korean J Hepatol. 2013 ; 2013(1) : 46-51.
  23. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of non-alcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007 ; 22 : 1086-91. https://doi.org/10.1111/j.1440-1746.2006.04781.x
  24. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007 ; 30 : 2940-4. https://doi.org/10.2337/dc07-0792
  25. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013 ; 167 : 1109-17. https://doi.org/10.1016/j.ijcard.2012.09.085
  26. Sui XD, Deng HB, Liu TJ. Prevention and treatment of nonalcoholic fatty liver disease by traditional Chinese medicine. World Chin J Digestol. 2013 ; 21(18) : 1708-13. https://doi.org/10.11569/wcjd.v21.i18.1708
  27. Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary artery disease mortality in older women. Ann Epidermiol. 1993 ; 3 : 35-41. https://doi.org/10.1016/1047-2797(93)90007-Q
  28. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci. 1995 ; 10 : 414-21. https://doi.org/10.3346/jkms.1995.10.6.414
  29. Jun DW. Non-alcoholic fatty liver disease. Clin Mol Hepatol. 2011 ; 17(3s) : 332-6.
  30. Jun DW. Diet and exercise in nonalcoholic fatty liver disease. PG. 2013 ; 2013(1) : 41-5.
  31. Zimmerman HJ, Seeff LB. Enzymes in hepatic disease In: Goodly, E.E., (Ed), Diagnostic Enzymology. Philadelphia : Lea and Febiger Publisher. 1970 : 1-38.
  32. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasmaclearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology. 1985 ; 5 : 367-75. https://doi.org/10.1002/hep.1840050305
  33. Lee JH, Kang KH, Kim SH, Park JH, Cho CM, Kwon YO, Kim SK, Choi YH. The association of elevated alanine aminotransferase activity with obesity in health screenig subjects. Korean J Med. 2005 ; 69(1) : 46-54.
  34. Kim GS, Choi YS, Park YH. The relationship between Fatty Liver and Parameters of Metabolic Syndrome in the Non Alcoholic Health Screen Examinees. Kosin Med J. 2006 ; 21(1) : 207-17.
  35. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995 ; 22 : 1714-9. https://doi.org/10.1002/hep.1840220616
  36. Cho YK. Pathophysiology of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2008 ; 14(4s) : 42-53.
  37. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998 ; 22 : 222-6. https://doi.org/10.1038/sj.ijo.0800571
  38. Fassio F, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004 ; 40 : 820-6.